FRANKFURT: Pfizer and BioNTech’s COVID-19 vaccine has been given to 140,000 people in Britain, and the feedback on side effects and tolerability has been reassuring, BioNTech’s chief medical officer said on Thursday.
Britain was the first to approve the shot for emergency use on Dec. 3, followed by Canada and the US Food and Drug Administration.
“In Britain, 140,000 people have been vaccinated by now and the tolerability data are exactly as we have shown in our clinical trial,” Chief Medical Officer Oezlem Tuereci said in a webcast call with German Chancellor Angela Merkel.
She said side effects have been mild to moderate and short-lived and similar to those typically seen in other commonly used vaccines.
The German biotech firm’s Chief Executive Ugur Sahin said in the call that he was confident that normal life could resume by next winter.

UK’s vaccine approval raises world’s hopes for COVID-19 fight UK authorizes Pfizer coronavirus vaccine for emergency use

A new map points out U.S. rivers most worth protecting
Exhaling may speed up reaction times
A medieval remedy could offer ideas for beating antibiotic resistance
In the wake of the flood, could Nepal avert the next disaster?
‘The Deep End’ podcast is back to explore what makes your voice yours
Magnetism may have helped kick-start our solar system
Lebanon: one in five children goes to bed hungry, says UNICEF
Malaysia: UN agency urges safeguards after refugees returned to Myanmar
New Ocean Report Warns of Rising Seas, Ocean Heat and Acidification